JPS6351705B2 - - Google Patents
Info
- Publication number
- JPS6351705B2 JPS6351705B2 JP60133740A JP13374085A JPS6351705B2 JP S6351705 B2 JPS6351705 B2 JP S6351705B2 JP 60133740 A JP60133740 A JP 60133740A JP 13374085 A JP13374085 A JP 13374085A JP S6351705 B2 JPS6351705 B2 JP S6351705B2
- Authority
- JP
- Japan
- Prior art keywords
- silicone rubber
- parts
- rubber composition
- composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 239000004945 silicone rubber Substances 0.000 claims description 27
- 229920002379 silicone rubber Polymers 0.000 claims description 16
- 229920002529 medical grade silicone Polymers 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
- 150000004679 hydroxides Chemical class 0.000 claims description 5
- 150000002484 inorganic compounds Chemical class 0.000 claims description 5
- 229910010272 inorganic material Inorganic materials 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- -1 polysiloxane Polymers 0.000 description 9
- 229920001296 polysiloxane Polymers 0.000 description 9
- 230000005251 gamma ray Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000001451 organic peroxides Chemical class 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910021485 fumed silica Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 125000005372 silanol group Chemical group 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229940043430 calcium compound Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 1
- DMWVYCCGCQPJEA-UHFFFAOYSA-N 2,5-bis(tert-butylperoxy)-2,5-dimethylhexane Chemical compound CC(C)(C)OOC(C)(C)CCC(C)(C)OOC(C)(C)C DMWVYCCGCQPJEA-UHFFFAOYSA-N 0.000 description 1
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OQVYMXCRDHDTTH-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)-2-[4-(diethoxyphosphorylmethyl)pyridin-2-yl]pyridine Chemical compound CCOP(=O)(OCC)CC1=CC=NC(C=2N=CC=C(CP(=O)(OCC)OCC)C=2)=C1 OQVYMXCRDHDTTH-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 229910019440 Mg(OH) Inorganic materials 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000011417 postcuring Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001721 transfer moulding Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
(産業上の利用分野)
本発明は医療用シリコーンゴム組成物、特には
γ線照射による滅菌処理後の溶出試験においても
PH変化、過マンガン酸カリ消費量などの少ない医
療用シリコーンゴム成形品、血液浄化器用部品、
血液回路用部品、カテーテル、チーブ、例えば人
工腎臓用ダイアライザー部品、血漿分離器用部
品、血液濾過用部品、人工胃シートなどに用いら
れるゴム部品を与えるシリコーンゴム組成物に関
するものである。
(従来の技術)
医療用ゴム成形品については無毒性、生体適合
性、非血液凝固性(抗血栓性)にすぐれていると
いうことからシリコーンゴム成形品が体内外用と
して広く使用されており、これは人工臓器用とし
ても使用されている。
この医療用シリコーンゴム成形品は加工メーカ
ーによつて成形されたのち水蒸気、エチレンオキ
サイドガスなどで滅菌し、完全密封包装されて市
場に出されるが、これには包装時における作業環
境下で汚染される危険が高く、さらにエチレンオ
キサイドガスによる滅菌では残存するエチレンオ
キサイドガスの毒性に問題がある。
そのため、この医療用シリコーンゴム成形品に
ついては完全密封包装後にγ線照射をして滅菌す
るという方法が提案されており、これによれば包
装時の汚染やエチレンオキサイドガスの残留など
の問題点も解消されるけれども、この場合にはγ
線照射によつて成形品中に水可溶性の酸性物質が
生成するために、この成形品についての品質基準
を定めた透析型人工腎臓基準(案)や輸液用プラ
スチツク容器試験などの溶出テストにおいて抽出
水のPH変化が大きくなつて規格に対して不合格に
なるという新しい問題が提起されている。
したがつて、この問題解決のために、シリコー
ンゴム組成物の配合、硬化用解媒の選択、ポスト
キユアー条件などが検討され、湯洗、溶剤抽出の
採用なども試みられているが、未だに完全な対策
は見出されていない。
(発明の構成)
本発明はこのような問題点を解決することので
きる医療用シリコーンゴム組成物に関するもので
あり、これは1)シリコーンゴム組成物100重量
部、2)カルシウム、マグネシウムの酸化物、水
酸化物、炭酸化物から選択される少なくとも1種
の無機化合物0.1〜2.0重量部とからなることを特
徴とするものである。
すなわち、本発明者らは完全密封包装された医
療用シリコーンゴム成形品のγ線照射による滅菌
処理における前記したような問題点を解決する方
法について種々検討した結果、この成形品を作る
ために使用するシリコーンゴム組成物中にカルシ
ウム、マグネシウムの酸化物、水酸化物、炭酸化
物を添加すると、この組成から作られた成形品
は、γ線照射されてもその抽出水のPH変化が小さ
く、過マンガン酸カリ消費量も少なくなるという
ことを見出し、このカルシウム、マグネシウム化
合物の種類、配合量などについての研究を進めて
本発明を完成させた。
本発明の組成物を構成する第1成分としてのシ
リコーンゴム組成物はこの種成形品に従来から使
用されている公知のものでよい。したがつて、こ
のシリコーンゴム組成物としては有機過酸化物に
よるラジカル反応架橋によりゴム状弾性体となる
もの、オルガノハイドロジエンポリシロキサンと
白金系触媒に代表される付加反応硬化させる為の
硬化触媒とを添加した、いわゆる付加反応架橋に
より硬化するもののいずれであつてもよく、これ
は平均単位式
(Industrial Application Field) The present invention also applies to medical silicone rubber compositions, especially in elution tests after sterilization by γ-ray irradiation.
Medical silicone rubber molded products with low pH changes and potassium permanganate consumption, parts for blood purifiers,
The present invention relates to a silicone rubber composition that provides rubber parts for use in blood circuit parts, catheters, tubes, such as dialyzer parts for artificial kidneys, plasma separator parts, blood filtration parts, artificial stomach sheets, and the like. (Prior art) Regarding medical rubber molded products, silicone rubber molded products are widely used for internal and external use because they are non-toxic, biocompatible, and have excellent non-blood coagulation properties (antithrombotic properties). are also used for artificial organs. This medical silicone rubber molded product is molded by a processing manufacturer, then sterilized using water vapor, ethylene oxide gas, etc., and placed on the market in completely sealed packaging. Furthermore, sterilization using ethylene oxide gas poses a problem with the toxicity of the remaining ethylene oxide gas. Therefore, a method of sterilizing medical silicone rubber molded products by irradiating them with gamma rays after completely sealed packaging has been proposed, but this method also poses problems such as contamination during packaging and residual ethylene oxide gas. However, in this case γ
Because water-soluble acidic substances are generated in molded products due to radiation irradiation, they are extracted during elution tests such as the dialysis-type artificial kidney standards (draft) that establish quality standards for these molded products and tests on plastic containers for infusions. A new problem has been raised in which the PH change in water becomes large enough to cause it to fail the standard. Therefore, in order to solve this problem, the formulation of the silicone rubber composition, selection of curing solvent, post-cure conditions, etc. have been studied, and attempts have been made to use hot water washing and solvent extraction, but there is still no complete solution. No countermeasures have been found. (Structure of the Invention) The present invention relates to a medical silicone rubber composition that can solve these problems, and includes: 1) 100 parts by weight of a silicone rubber composition; 2) oxides of calcium and magnesium; 0.1 to 2.0 parts by weight of at least one inorganic compound selected from hydroxides, hydroxides, and carbonates. That is, the present inventors have studied various ways to solve the above-mentioned problems in the sterilization process of medical silicone rubber molded products that are completely sealed and packaged by γ-ray irradiation, and as a result, we have developed a method that can be used to make this molded product. When oxides, hydroxides, and carbonates of calcium and magnesium are added to a silicone rubber composition, molded products made from this composition exhibit a small PH change in the extracted water even when irradiated with gamma rays. They discovered that the amount of potassium manganate consumed was also reduced, and conducted research on the types and amounts of calcium and magnesium compounds, and completed the present invention. The silicone rubber composition as the first component constituting the composition of the present invention may be any known silicone rubber composition conventionally used in molded articles of this type. Therefore, this silicone rubber composition can be made into a rubber-like elastic body by radical reaction crosslinking with an organic peroxide, or a curing catalyst for addition reaction curing, such as organohydrodiene polysiloxane and a platinum-based catalyst. The average unit formula is
【式】で示され、式中a=
1.90〜2.05、Rはメチル基、エチル基、プロピル
基、ブチル基などのアルキル基、ビニル基、アリ
ル基などのアルケニル基、フエニル基、トリル基
などのアリール基またはこれらの基の炭素原子に
結合した水素原子の一部または全部をハロゲン原
子、シアノ基などで置換したクロロメチル基、
3,3,3―トリフルオロプロピル基、シアノメ
チル基などのような同一または異種の非置換また
は置換1価炭化水素基で、好ましくはその80モル
%がメチル基であり、0.1〜0.5モル%がビニル基
とされるオルガノポリシロキサンで、好ましくは
25℃に於る粘度が100cS以上望ましくは1000cS以
上とされるものをベースとするものであればよ
い。
なお、本オルガノポリシロキサンの末端はシラ
ノール基、メチル基、ビニル基で封鎖されたも
の、特にはビニル基で封鎖されたものが望まし
い。
このシリコーンゴム組成物は上記したオルガノ
ポリシロキサンにシリカ系充填剤を配合したもの
が一般的とされ、この充填剤としてはフユームド
シリカ、沈降性シリカ、石英粉末、けいそう土な
どが代表的なものとして例示されるが、これらは
その粒子径が50μm以下のものとすることがよ
く、この添加量はオルガノポリシロキサン100重
量部に対し20〜200重量部の範囲とすればよい。
なお、この組成物はシリカ分散剤としてアルコキ
シ基、シラノール基などを含有するシランや低分
子シロキサン、さらには着色のための無機質顔料
などを含んだものとしてもよい。
このシリコーン組成物は有機過酸化物の存在下
でのラジカル架橋により加熱硬化させることがで
き、この有機過酸物としてはベンゾイルパーオキ
サイド、2,4―ジクロロベンゾイルパーオキサ
イド、オルソクロロベンゾイルパーオキサイド、
ジ―t―ブチルパーオキサイド、ジクミルパーオ
キサイド、2,5―ビス(t―ブチルパーオキ
シ)―2,5―ジメチルヘキサンなどが例示され
る。
しかし、このシリコーンゴム組成物は付加反応
型のものとしてもよく、この場合には分子中にけ
い素原子に結合した水素原子を少なくとも2個有
するオルガノハイドロジエンポリシロキサンと白
金系触媒を添加することが最も一般的とされる。
このオルガノハイドロジエンポリシロキサンして
は次式
[Formula], where a = 1.90 to 2.05, R is an alkyl group such as a methyl group, an ethyl group, a propyl group, a butyl group, an alkenyl group such as a vinyl group or an allyl group, a phenyl group, a tolyl group, etc. Chloromethyl groups in which part or all of the hydrogen atoms bonded to the carbon atoms of aryl groups or these groups are substituted with halogen atoms, cyano groups, etc.
Same or different unsubstituted or substituted monovalent hydrocarbon groups, such as 3,3,3-trifluoropropyl group, cyanomethyl group, etc., preferably 80 mol% of which is a methyl group, and 0.1 to 0.5 mol% of which is a methyl group. An organopolysiloxane having a vinyl group, preferably
Any material may be used as long as it has a viscosity of 100 cS or more, preferably 1000 cS or more at 25°C. Note that the terminals of the present organopolysiloxane are preferably capped with silanol groups, methyl groups, or vinyl groups, particularly those capped with vinyl groups. This silicone rubber composition is generally made by blending the above-mentioned organopolysiloxane with a silica-based filler, and typical fillers include fumed silica, precipitated silica, quartz powder, and diatomaceous earth. For example, these particles preferably have a particle size of 50 μm or less, and the amount added may range from 20 to 200 parts by weight per 100 parts by weight of the organopolysiloxane.
The composition may also contain a silane or low-molecular siloxane containing an alkoxy group, a silanol group, etc. as a silica dispersant, or an inorganic pigment for coloring. This silicone composition can be heat-cured by radical crosslinking in the presence of an organic peroxide, and examples of the organic peroxide include benzoyl peroxide, 2,4-dichlorobenzoyl peroxide, orthochlorobenzoyl peroxide,
Examples include di-t-butyl peroxide, dicumyl peroxide, and 2,5-bis(t-butylperoxy)-2,5-dimethylhexane. However, this silicone rubber composition may be of an addition reaction type, in which case an organohydrodiene polysiloxane having at least two hydrogen atoms bonded to silicon atoms in the molecule and a platinum catalyst are added. is said to be the most common.
This organohydrodiene polysiloxane has the following formula:
で示されるものが例示されるが、この添加量は上
記したオルガノポルシロキサン中のビニル基量に
対し≡SiH/≡Si(CH=CH2)=0.5〜5.0(モル比)
を与える範囲とすればよい。また、こゝに添加さ
れる白金系触媒としては塩化白金酸、塩化白金酸
とアルコール、エーテル、アルデヒド、オレフイ
ン、ビニルシロキサンとの錯塩などが一般的であ
り、これはこのシリコーンゴム組成物に対し1〜
100ppmの範囲で添加すればよい。
他方、本発明の組成物を構成する第2成分とし
ての無機化合物はカルシウム、マグネシウムの酸
化物、水酸化物、炭酸化物から選択される少なく
とも1種のものとされ、これらの化合物について
はCaO、Ca(OH)2、CaCO3、Ca(HCO3)2、
MgO、Mg(OH)2、MgCO3、3MgCO3・Mg
(OH)2・3H2Oなどが例示されるが、目的とする
効果およびシリコーンゴムに対する影響度などか
らこれらの中では炭酸化物が特に好適とされる。
また、これらの添加量はこの化合物の塩基度によ
つて異なるが、上記した第1成分としてのシリコ
ーンゴム組成物100重量部に対しこれが0.1重量部
以下では目的とするγ線照射後の抽出水のPH変動
抑制効果が小さく、2.0重量部以上とするとこれ
らの塩基性によつてPH変動が大きくなるおそれが
あるので、これに0.1〜2.0重量部の範囲とする必
要がある。
本発明の組成物は上記した第1成分と第2成分
の所定量を均一に混合することによつて得られ、
この混合に当つてはこれらを粉末状で2本ロール
などで混練りしてもよいが、分散不良を防ぐため
にはまず高濃度の3本ロールで分散させてマスタ
ーバツチを作り、これを添加するようにすること
がよい。
本発明の組成物から医療用シリコーンゴム成形
品を得るには、この組成物に前記した有機過酸化
物、白金系化合物などの硬化触媒を添加したの
ち、常法にしたがつてプレス、インジエクシヨ
ン、トランスフアーモールド、押出しなどの成形
法で所望の形状の成形品を作り、120〜400℃で数
秒〜10分程度、必要に応じ加圧下に加熱して硬化
させ、ついで完全硬化や加硫剤残渣処理のために
必要に応じて150〜200℃で2〜4時間ポストキユ
アーをしたり、70〜90℃での湯洗処理を行えばよ
い。このようにして得られた成形品は公知の方
法、例えばオレフイン系プラスチツクフイルム、
ポリイミドアミドフイルム、セルロースフイルム
などのヒートシールによつて完全密封包装され、
ついでγ線照射で滅菌処理されて製品とされる
が、このγ線の照射量は2〜8Mradとすればよ
く、本発明の組成物から作られた成型品はこのγ
線照射によつてもその抽出水のPH変化が小さく、
過マンガン酸カリウム消費量も少ないので各種の
テストに不合格となることが非常に少なくなると
いう有利性が与えられる。
つぎに本発明の実施例をあげるが、例中の部は
重量部を、また粘度は25℃での測定値を示したも
のである。
実施例 1
分子鎖末端が(CH2=CH)(CH3)2SiO0.5で封
鎖された(CH3)2SiO単位99.8モル%、(CH3)
(CH2=CH)SiO単位0.2モル%からなるオルガノ
ポルシロキサン生ゴム100部に、(CH3)3SiO0.5単
位で表面処理された比表面積が230m2/gのヒユ
ームドシリカ40部、分子鎖末端がシラノール基で
封鎖された式 For example, the amount of addition is ≡SiH/≡Si (CH=CH 2 )=0.5 to 5.0 (molar ratio) with respect to the amount of vinyl groups in the organoporsiloxane described above.
It is sufficient to set the range to give . In addition, platinum-based catalysts that are commonly added include chloroplatinic acid and complex salts of chloroplatinic acid and alcohols, ethers, aldehydes, olefins, and vinyl siloxanes, which are suitable for this silicone rubber composition. 1~
It may be added within a range of 100ppm. On the other hand, the inorganic compound as the second component constituting the composition of the present invention is at least one selected from oxides, hydroxides, and carbonates of calcium and magnesium, and these compounds include CaO, Ca(OH) 2 , CaCO3 , Ca( HCO3 ) 2 ,
MgO, Mg(OH) 2 , MgCO3 , 3MgCO3・Mg
(OH) 2.3H 2 O and the like are exemplified, but among these, carbonates are particularly preferred in view of the desired effect and degree of influence on silicone rubber.
The amount of these added varies depending on the basicity of this compound, but if it is less than 0.1 part by weight based on 100 parts by weight of the silicone rubber composition as the first component, the target extracted water after γ-ray irradiation will be The effect of suppressing PH fluctuations is small, and if the amount exceeds 2.0 parts by weight, there is a risk that PH fluctuations will become large due to their basicity. The composition of the present invention is obtained by uniformly mixing predetermined amounts of the above-described first component and second component,
For this mixing, these powders may be kneaded using two rolls, but in order to prevent poor dispersion, first disperse them using three rolls at a high concentration to create a masterbatch, and then add this. It is better to In order to obtain a medical silicone rubber molded article from the composition of the present invention, a curing catalyst such as the above-mentioned organic peroxide or platinum compound is added to the composition, and then the composition is pressed, injected, etc. in a conventional manner. A molded product in the desired shape is made using a molding method such as transfer molding or extrusion, and is heated at 120 to 400°C for a few seconds to 10 minutes under pressure if necessary to cure it, and then completely cured and removes the vulcanizing agent residue. For treatment, post-curing may be performed at 150 to 200°C for 2 to 4 hours, or hot water washing may be performed at 70 to 90°C, if necessary. The molded product thus obtained can be manufactured using known methods such as olefin plastic film,
Completely sealed and packaged with heat sealing of polyimide amide film, cellulose film, etc.
The product is then sterilized by γ-ray irradiation, but the dose of γ-ray irradiation may be between 2 and 8 Mrad, and molded products made from the composition of the present invention can be sterilized by γ-ray irradiation.
Even when irradiated with radiation, the pH change of the extracted water is small.
The low consumption of potassium permanganate also provides the advantage of significantly fewer failures in various tests. Next, examples of the present invention will be given, in which parts are by weight, and viscosity is a value measured at 25°C. Example 1 Molecular chain ends were blocked with (CH 2 =CH) (CH 3 ) 2 SiO 0.5 (CH 3 ) 2 SiO units 99.8 mol%, (CH 3 )
100 parts of organoporsiloxane raw rubber consisting of 0.2 mol% of (CH 2 =CH) SiO units, 40 parts of fumed silica with a specific surface area of 230 m 2 /g surface-treated with 0.5 units of (CH 3 ) 3 SiO, and molecular chain terminals Formulas capped with silanol groups
【式】で示されるジ
メチルポリシロキサン1.0部を添加し、ニーダー
中で180℃/2時間の熱処理を行なつてシリコー
ンゴム組成物Aを作つた。
つぎに、この組成物A100部に第1表に示した
カルシウム、マグネシウム化合物を第1表に示し
た量で添加すると共に、加硫剤C―8A〔信越化学
工業(株)製商品名、2,5―ビス(t―ブチルパー
オキシ)―2,5―ジメチルヘキサンの80%ペー
スト〕を添加し、これを170℃×10分の条件でプ
レス加硫して2mmのシートとし、200℃/4時間
のポストキユアーを行なつたのち、このシートに
3Mradまたは6Mradのγ線照射を行ない、この
シートにいて透析型人工腎臓装置基準試験の溶出
テスト法に準じて抽出液のPH変化、過マンガン酸
カリウム消費量を測定したところ、第1表に併記
たとおりの結果が得られた。A silicone rubber composition A was prepared by adding 1.0 part of dimethylpolysiloxane represented by the formula and heat-treating the mixture in a kneader at 180°C for 2 hours. Next, the calcium and magnesium compounds shown in Table 1 were added to 100 parts of this composition A in the amounts shown in Table 1, and vulcanizing agent C-8A [trade name, 2, manufactured by Shin-Etsu Chemical Co., Ltd. , 80% paste of 5-bis(t-butylperoxy)-2,5-dimethylhexane] was press-cured at 170°C for 10 minutes to form a 2 mm sheet, and then vulcanized at 200°C/ After 4 hours of post cure, this sheet
After 3Mrad or 6Mrad of γ-ray irradiation, we measured the PH change of the extract and the amount of potassium permanganate consumed on this sheet according to the elution test method of the dialysis type artificial kidney device standard test, and the results are also listed in Table 1. The results were as expected.
【表】
実施例 2
実施例1において使用した炭酸マグネシウムの
添加量を第2表に示したように変化させて得た組
成物から、実施例1と同じようにしてシートを作
り、このシートのγ線照射後の抽出液のPH変化、
過マンガン酸カリウム消費量をしらべたところ、
第2表に示したとおりの結果が得られた。[Table] Example 2 A sheet was made in the same manner as in Example 1 from a composition obtained by changing the amount of magnesium carbonate used in Example 1 as shown in Table 2. PH change of extract after γ-ray irradiation,
When we looked at the amount of potassium permanganate consumed, we found that
The results shown in Table 2 were obtained.
【表】【table】
【表】
実施例 3
分子鎖末端がジメチルビニルシリル基で封鎖さ
れた、粘度が5000cSのジメチルポリシロキサン
90部に、SiO2単位、(CH3)3SiO0.5単位、(CH2=
CH)(CH3)2SiO0.5単位からなり、SiO2/
(CH3)3SiO0.5+(CH2=CH)(CH3)2SiO0.5=1.0
(モル比)でビニル基含有量が1重量%であるシ
ロキサン共重合体10部、実施例1で使用した表面
処理ヒユームドシリカ30部、メチルハイドロジエ
ンポリシロキサン・KF99〔信越化学工業(株)製商品
名〕1.5部を添加してシリコーンゴム組成物Bを
作り、ついでこれに塩化白金酸の2―エチルヘキ
サノール溶液(白金含量2%)0.05部と第3表に
示した量のCaCO3、MgCO3とを添加して均一に
混合し、この組成物について実施例1と同じ試験
を行なつたところ、第3表に併記したとおりの結
果が得られた。[Table] Example 3 Dimethylpolysiloxane with a viscosity of 5000 cS, whose molecular chain terminals are capped with dimethylvinylsilyl groups
90 parts, SiO 2 unit, (CH 3 ) 3 SiO 0.5 unit, (CH 2 =
CH) (CH 3 ) 2 Consists of 0.5 units of SiO 2 /
(CH 3 ) 3 SiO 0.5 + (CH 2 = CH) (CH 3 ) 2 SiO 0.5 = 1.0
10 parts of a siloxane copolymer with a vinyl group content of 1% by weight (molar ratio), 30 parts of the surface-treated fumed silica used in Example 1, methylhydrodiene polysiloxane KF99 [product manufactured by Shin-Etsu Chemical Co., Ltd.] Silicone rubber composition B was prepared by adding 1.5 parts of chloroplatinic acid in 2-ethylhexanol (platinum content 2%) and 0.05 parts of chloroplatinic acid in 2-ethylhexanol (platinum content 2%) and the amounts of CaCO 3 and MgCO 3 shown in Table 3. When this composition was subjected to the same test as in Example 1, the results shown in Table 3 were obtained.
【表】
実施例 4
市販されている医療用シリコーンゴムコンパウ
ンド・KE153U、KE1551U、KE951U、
KE1920A、B(液状ゴム)〔いずれも信越化学工
業(株)製商品名〕に第4表に示した量のMgCO3を
添加して得た組成物について、実施例1と同じ試
験を行なつたところ、第4表に併記したとおりの
結果が得られた。[Table] Example 4 Commercially available medical silicone rubber compounds: KE153U, KE1551U, KE951U,
The same test as in Example 1 was conducted on compositions obtained by adding MgCO 3 in the amount shown in Table 4 to KE1920A, B (liquid rubber) [both trade names manufactured by Shin-Etsu Chemical Co., Ltd.]. As a result, the results shown in Table 4 were obtained.
【表】【table】
Claims (1)
物、炭酸化物から選択される少なくとも1種の
無機化合物 0.1〜2.0重量部 からなることを特徴とする医療用シリコーンゴム
組成物。 2 無機化合物が酸化マグネシウム、炭酸マグネ
シウム、塩基性炭酸マグネシウムから選択された
ものである特許請求の範囲第1項記載の医療用シ
リコーンゴム組成物。 3 無機化合物が水酸化カルシウムまたは炭酸カ
ルシウムである特許請求の範囲第1項記載の医療
用シリコーンゴム組成物。[Claims] 1 1 Silicone rubber composition 100 parts by weight 2 At least one inorganic compound selected from oxides, hydroxides, and carbonates of calcium and magnesium 0.1 to 2.0 parts by weight Medical silicone rubber composition. 2. The medical silicone rubber composition according to claim 1, wherein the inorganic compound is selected from magnesium oxide, magnesium carbonate, and basic magnesium carbonate. 3. The medical silicone rubber composition according to claim 1, wherein the inorganic compound is calcium hydroxide or calcium carbonate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60133740A JPS61290957A (en) | 1985-06-19 | 1985-06-19 | Medical silicone rubber composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60133740A JPS61290957A (en) | 1985-06-19 | 1985-06-19 | Medical silicone rubber composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1235354A Division JPH0622588B2 (en) | 1989-09-11 | 1989-09-11 | Medical silicone rubber composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61290957A JPS61290957A (en) | 1986-12-20 |
JPS6351705B2 true JPS6351705B2 (en) | 1988-10-14 |
Family
ID=15111810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60133740A Granted JPS61290957A (en) | 1985-06-19 | 1985-06-19 | Medical silicone rubber composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61290957A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008517796A (en) * | 2004-10-25 | 2008-05-29 | ナノン アクティーゼルスカブ | Method for producing silicone rubber product and product obtained by the method |
JP2016002103A (en) * | 2014-06-13 | 2016-01-12 | 信越化学工業株式会社 | Addition-curable silicone rubber composition for manufacturing medical balloon catheter |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4893658A (en) * | 1972-03-16 | 1973-12-04 | ||
JPS5227180A (en) * | 1975-08-26 | 1977-03-01 | Chikara:Kk | Device for conveying cooks by using train |
JPS5363615A (en) * | 1976-09-07 | 1978-06-07 | Leveen Harry H | Flexible pipe |
JPS5879054A (en) * | 1981-11-05 | 1983-05-12 | Toshiba Silicone Co Ltd | Thermally vulcanizable silicone rubber composition |
-
1985
- 1985-06-19 JP JP60133740A patent/JPS61290957A/en active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4893658A (en) * | 1972-03-16 | 1973-12-04 | ||
JPS5227180A (en) * | 1975-08-26 | 1977-03-01 | Chikara:Kk | Device for conveying cooks by using train |
JPS5363615A (en) * | 1976-09-07 | 1978-06-07 | Leveen Harry H | Flexible pipe |
JPS5879054A (en) * | 1981-11-05 | 1983-05-12 | Toshiba Silicone Co Ltd | Thermally vulcanizable silicone rubber composition |
Also Published As
Publication number | Publication date |
---|---|
JPS61290957A (en) | 1986-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0110537B1 (en) | Surface treatment of inorganic fillers | |
EP0438221B1 (en) | Improved adhesion of silicone sealants | |
EP0296878B1 (en) | Modified polysiloxane-coated sanitary rubber article and process for its production | |
JPH02283764A (en) | Reinforcing silica filler and its manufacture | |
EP3388488B1 (en) | Addition-curable silicone rubber composition and silicone rubber | |
JPH0514742B2 (en) | ||
KR20170010313A (en) | Addition-curable liquid silicone rubber composition | |
JP2643768B2 (en) | Thermosetting silicone rubber composition | |
JP2859362B2 (en) | Neutral cured silicone sealant | |
EP3377036B1 (en) | Room temperature curable compositions | |
WO2009138797A1 (en) | Silicone rubber compositions | |
JP3339946B2 (en) | Needle | |
WO2013137472A1 (en) | Silicone elastomer composition, elastic material for medical device, and medical balloon | |
JP6848760B2 (en) | Sealing material for coolant | |
US11512237B2 (en) | Room temperature curable compositions | |
JP3105151B2 (en) | Composition for acoustic lens | |
JPH02124977A (en) | Silicone rubber composition | |
JP3301293B2 (en) | Platinum catalyst composition, method for producing the same, and curable organopolysiloxane composition | |
JPS6351705B2 (en) | ||
EP0314314B1 (en) | Filled compositions | |
EP2883903A1 (en) | Fluorosilicone rubber composition | |
JPH08259817A (en) | Additive for preventing formation of nitrosoamine in silicone article | |
JP3465943B2 (en) | Self-fusing silicone rubber composition | |
JPS62158755A (en) | Silicone composition | |
JP2004182908A (en) | Method for producing liquid silicone composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |